June 25, 2024

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Steven Ralston, CFA
312-265-9426
sralston@zacks.com

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

VolitionRx Ltd (NYSE: VNRX)

VNRX: Cost cutting being implemented in a plan to be cash flow neutral in 2025. Revenues from Nu.Q Vet Test Expected to Accelerate During 2H 2024
Two Key R&D Efforts in 2024/25:
1) Breakthrough Cancer Detection Method
2) Nu.Q NET for Sepsis

A discounted cash flow (DCF) model that applies a 10% discount rate and a 2% terminal growth rate indicates a price target of $3.85 per share.

Current Price (06/24/24)	$0.68
Valuation	**$3.85**

OUTLOOK

Volition's **Nu.Q Vet Canine Cancer Screening Test** are **being launched in the U.S. and Europe** by Antech on its Element I+ diagnostic point-of-sale platform and **in Japan** by Fujifilm Vet Systems. Sales are expected to accelerate during 2H 2024.

Nu.Q Discover has **pipeline of opportunities** valued at **over $1 million.**

Breakthrough cancer detection method (Capture-PCR) is being presented at cancer specific conferences & **research continues** on developing specific biomarkers for multiple cancers in proof of concept studies.

SUMMARY DATA

52-Week High	**$1.57**
52-Week Low	**$0.55**
One-Year Return (%)	**-54.84**
Beta	**1.17**
Average Daily Volume (shrs.)	**101,846**
Shares Outstanding (million)	**82.8**
Market Capitalization ($mil.)	**$55.6**
Short Interest Ratio (days)	**5.0**
Institutional Ownership (%)	**9.4**
Insider Ownership (%)	**8.0**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/M**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/M**
P/E using 2022 Estimate	**N/M**
P/E using 2023 Estimate	**N/M**

Risk Level	**Above Average**
Type of Stock	**Small-Growth**
Industry	**Med-Tech/Diagnostic**

ZACKS ESTIMATES

Revenue
(in thousands of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2021	25 A	25 A	25 A	14 A	91 A
2022	114 A	40 A	33 A	120 A	306 A
2023	115 A	216 A	165 A	244 A	775 A
2024	171 A	345 E	600 E	925 E	2,041 E

Earnings per Share)
(EPS is operating earnings before non-recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2021	-$0.12 A	-$0.10 A	-$0.13 A	-$0.15 A	-$0.51 A
2022	-$0.14 A	-$0.14 A	-$0.14 A	-$0.13 A	-$0.55 A
2023	-$0.15 A	-$0.14 A	-$0.11 A	-$0.11 A	-$0.50 A
2024	-$0.10 A	-$0.09 E	-$0.07 E	-$0.05 E	-$0.29 E

Quarterly EPS may not equal annual EPS total due to rounding.

© Copyright 2024, Zacks Investment Research. All Rights Reserved.

SIGNIFICANT OPERATIONAL UPDATES & 1Q 2024 FINANCIAL RESULTS

Management has undertaken a **significant cost cutting program** with the **goal of ensuring that Volition is cash flow neutral in 2025**. In addition to the cost reductions taken in 1Q 2024 resulting in a 6.9% reduction in operating expenses, additional actions were taken in order to reduce expenditures and cash burn. Cost reduction measures were implemented in the areas of R&D and sales & marketing with **the intent of achieving a $10 million reduction in annualized expenses**. Some of the actions announced include that the Directors intend to take 50% of their fees in equity for a least six (6) months, that senior management intends to take a percentage of their salaries (between from 10% to 50%) in equity for a least six (6) months ranging from 10% to 50% and that the payments of any cash bonuses have been postponed indefinitely.

Management expects that revenues from Nu.Q Vet will accelerate during 2H 2024 driven by the product launches by two large distributors, **Antech Diagnostics** (part of the Mars Pet Care Group) and **Fujifilm Vet Systems**. Antech has successfully transferred the processing of the Nu.Q Vet Cancer test to its proprietary Element i+ Immunodiagnostic Analyzer point-of-care diagnostic platform and has announced the launch of the test in the U.S. and Europe at an aggressive list price of $35 to veterinarians. Fujifilm Vet Systems launched the Nu.Q Vet Cancer test at the World Veterinary Cancer Congress held in Tokyo in March 2024 and is also attractively pricing the test at below $40.

On the commercialization side, **Volition has already received $23 million from signing initial agreements and milestone payments** from Nu.Q Vet. Management expects to receive a $5 million milestone payment based on feline product development within the next year and a half. Management also expects to receive **licensing milestone payments from Nu.Q NET and Capture-PCR.**

Management also expects to receive further meaningful government non-dilutive funding. The company has either applied or is in the process of applying for $25 million in non-dilutive grants from funding bodies in the U.S. and $18 million within Europe.



Volition Presentation May 2024

Around mid-year 2024, a substantial amount of clinical data is expected to be received for both **Nu.Q NETs** (particularly for sepsis) **and Capture-PCR** (a potential breakthrough cancer detection method). The data should provide scientific and clinical evidence to support these potentially breakthrough technologies.

- **The results of two large retrospective sepsis studies** are expected to be presented at **ESICM** (European Society of Intensive Care) in Barcelona in **October 2024**.
- **A paper on the Capture-PCR** breakthrough method is **expected to be completed by mid-2024 for peer review.**
- **Several abstracts** on Capture-PCR and Nu.Q technology for lung cancer **have been submitted** for consideration to **ESMO 2024** to be held in Barcelona in **mid-September 2024**

First Quarter 2024 Financial Results

On May 13, 2024, VolitionRx reported financial results for the first quarter ending March 31, 2024. Total revenues increased 14.5% YOY to $171,535 compared to $149,808 in the first quarter of 2023. S**ervice revenue** (Nu.Q Discover) **increased 643%** to $39,776 **while product revenue** from sales of the Nu.Q Vet cancer screening and H3.1 kits **declined 8.8%** to $131,759.

Operating expenses decreased 6.9% from $9.19 million to $8.56 million**. R&D expenses declined 7.3%** to approximately $3.59 million. **G&A expenses declined 5.6%** to approximately $4.63 million due to lower personnel expenses, legal expenses and stock-based compensation; full-time employees (FTE) decreased from 21 to 20. Sales and marketing expenses decreased 2.0% from 1.71 million to 1.67 million due primarily stock-based compensation declining 52.8% to $116,414, which was partially offset by an increase in personnel expenses as FTE increased from 18 to 22.

For the first quarter, VolitionRx reported a net loss of $8.47 million (or $0.10 per diluted share) versus a net loss of approximately $8.87 million (or $0.15 per diluted share) in the comparable quarter last year.

Shares outstanding increased by 0.3% to 82,108,972 shares from 81,898,321 shares on December 31, 2023. As of March 31, 2024, Volition had $11.8 million cash-on-hand.

COMMERCIALIZTION OF Nu.Q VET CONTINUES

Volition Veterinary continues to expanded its distribution network through new supply agreements. The Nu.Q Vet Cancer Test is currently available in

- **the U.S.** (initial product launch in November 2020 through direct sales being processed at the GI Lab at Texas A&M University followed by IDEXX in January 2023),
- **the U.K.** & **Ireland** (launched in the U.K. and Ireland through the Veterinary Pathology Group, and in the U.K. through Nationwide Laboratories, both November 2023),
- **Portugal** (DNAtech - product launch in November 2022),
- **Singapore** (SAGE Healthcare),
- **Taiwan** (Vita Genomics - product launch in November 2023) and
- **Italy** (scil animal care company GmbH, an Antech company).
- **Japan (**Fujifilm Vet Systems - product launch in March 2024)



During 2023, Nu.Q Vet Cancer Screening Tests generated revenues of approximately **$475,000** on the sales of **over 58,000 tests. In 2024**, **Nu.Q Vet revenues are expected to ramp up** beginning in the second half of 2024 as two distributors (Antech and Fujifilm Vet Systems) come online. Both are aggressively coming to market with a price under $40 to veterinarians.

In late-March 2023, **VolitionRx received a $10 million up-front payment** from Heska on the signing of a licensing agreement that grants exclusive rights to commercialize Nu.Q Vet for canine cancer screening and monitoring at the point of care. Also, Heska was granted **non-exclusive rights to sell the Nu.Q Vet test kits through its reference laboratory network**. The payment for the kits and key components will be at pre-agreed prices, which should provide another revenue stream for VolitionRx.

In December 2023, Volition **received the $13 million** milestone payment from Heska (an Antech company, which is part of Mars Petcare), upon **completing the technology transfer** onto Heska's proprietary **Element i+ Immunodiagnostic Analyzer point-of-care diagnostic platform**, which was launched in 2020.



Volition Presentation May 2024

On March 20, 2024, Volition announced the signing of a **supply agreement with Fujifilm Vet Systems** Co. Ltd. for the Nu.Q Vet Cancer Test to veterinarians **in Japan**. The agreement allows Fujifilm Vet Systems to sell and perform canine cancer screening services with the Nu.Q Vet Cancer Test throughout its diagnostic network of 10 central reference laboratories that serve over 90% of the 12,000 veterinary clinics and hospitals in Japan.

Between March 21-24, 2024, **Fujifilm Vet Systems** introduced the Nu.Q Vet Cancer Test at its booth at the **World Veterinary Cancer Congress** in **Tokyo**. At the Congress, Dr. Heather Wilson-Robles **presented a poster** about the Nu.Q Vet Cancer Test.

Expected Nu.Q Vet Milestones in 2024/2025

- During mid-2024, Heska will begin offering the Nu.Q Vet Cancer Test on its Element I+ in-house diagnostic platform.

- **Fujifilm Vet Systems** Co. Ltd. is expected to launch for the Nu.Q Vet Cancer Test to veterinarians **in Japan** during 2024. The supply agreement includes a $5 million milestone payment (based on feline product development), which management expects to receive within the next year and a half.

Nu.Q DISCOVER – GROWING REVENUE BASE

VolitionRx offers laboratory services and contract research for external parties under the **Nu.Q Discover** moniker. These external parties include pharmaceutical companies, biotechnology companies and academic researchers, among others. Under **Nu.Q Discover**, Volition offers products (such as recombinant nucleosomes, antibodies, reagents, supply kits etc.) and processing services in order provide epigenetic profiling in disease models, pre-clinical testing and clinical trials.

The first Nu.Q Discover agreement was signed in the fourth quarter of 2021. In early 2022, the aggregate annual worth of the company's Nu.Q Discover contracts were roughly $200,000. Since then, the worth of contracts being pursued and signed has ramped up. **During 2023**, Nu.Q Discover generated **$300,000 in revenues**, and the **pipeline of Nu.Q Discover opportunities** is valued at **over $1 million.** In the first quarter of 2024, revenues from Nu.Q Discover increased 643% YOY to $39,776.

Due to the project-based nature of Nu.Q Discover contracts, the revenue stream tends to be lumpy quarter-to-quarter.

CAPTURE-PCR – BREAKTHROUGH CANCER DETECTION METHOD

Volition announced a **breakthrough cancer detection method** at **ESMO 2023** (European Society for Medical Oncology), which was followed up by an informative **webinar** with an informative **slide deck**. This **novel method** for detecting cancer through a blood test (liquid biopsy) is a **step change advancement** and was discovered through Volition's research focus on fragments of chromosomes that circulate in the bloodstream. Volition recognized that **particular combinations of DNA sequences that bind onto CTCF transcription factors only when cancer is present** and devised a technique

1) to **physically isolate these tumor-derived, cancer-associated DNA fragments from blood plasma** and


2) to **detect** these particular DNA sequences **with a simple, low cost blood test** (PCR liquid biopsy)

Volition is focusing on **detecting circulating tumor DNA** (ctDNA), which is difficult since ctDNA comprises roughly only 0.01% of the circulating cell-free DNA. Volition has developed a novel method of physically isolating tumor-derived DNA fragments from blood/plasma and removing all normal background DNA. The sample is then sequenced using a PCR test.

Thus far, the new **Capture-PCR** technique has been tested only in a small, preliminary proof of concept study, initially developed on a leukemia model. However, most of the ten biomarkers effectively identified a variety of common **solid cancers**. A panel of two PCR tests that detected 77% of **colorectal cancer** (CRC) cases with 92% specificity.

Notably, during this **preliminary proof of concept work**, another panel of two PCR tests detected multiple cancers, namely colorectal, breast, prostate and liver cancers. In the study, n=20 for each cancer type except n=13 for CRC.

Novel wet chemistry pathway for ctDNA analysis



VolitionRx Presentation March 2024

Also, 75% of Stage IV cancers were detected, but remarkably, **44% of Stage I were detected** and **33% of Stage II cancers were detected**. This aligns with one of Volition's key goals: **the identification of diseases with a simple, easy to use, low cost diagnostic test at the earliest stage possible in order to improve outcomes.**

Proof of principle for multi-cancer early detection using a 2-qPCR assay (90% specificity)

Solid cancers	patients	positive	sensitivity
• CRC	13	9	69%
• Breast	10	5	50%
• Prostate	10	5	50%
• Liver	10	6	60%
TOTAL	**43**	**25**	**58%**

Solid cancers	patients	positive	sensitivity
• Stage I	9	4	44%
• Stage II	9	3	33%
• Stage III	9	6	67%
• Stage IV	16	12	75%
TOTAL	**43**	**25**	**58%**

Volition Presentation October 2023

Expected Upcoming *Events - Capture-PCR*:

Capture-PCR has been presented a number of cancer specific conferences, including one for prostate cancer, liver cancer and lung cancer. Cancer specific abstracts and posters are expected to be presented at conferences in the second half of 2024

The **Capture-PCR** team is in the process of **optimizing the chemistry, along with** identifying **and developing specific biomarkers and panels for breast, prostate, lung, colorectal and liver cancers**. These proof of concept studies for each type of cancer are expected to have sample sizes between 50 and 200.

A **paper** on the **Capture-PCR** method of **isolating DNA sequences from CTCF transcription factors** and **testing for ctDNA cancer-associated DNA fragments** is being prepared for peer review and publication.

Volition's commercial strategy for Capture-PCR continues to be to enter into technology licensing contracts (which include up-front & milestone payments and/or royalties) and then to secure arrangements for the sales of key components. The company is already in discussions with interested parties, and a number of meetings are scheduled for further discussions.

Expected Capture-PCR Milestones in 2024

- **A paper on the Capture-PCR** breakthrough method is **expected to be completed by mid-2024 for peer review.**
- **Several abstracts** on Capture-PCR and Nu.Q technology for lung cancer **have been submitted** for consideration **to ESMO 2024**

Nu.Q NET – POTENTIAL FOR THE DIAGNOSIS & MONITORING OF SEPSIS

Sepsis is one of the leading of causes of death worldwide. Roughly 50 million cases are reported annually; these cases lead to approximately 11 million deaths. In addition, 40% of sepsis survivors have long term impairments, such as the loss of digits (fingers & toes) and/or cognitive deterioration (diminished memory and concentration).

Notably, in 2016, research work **refined the definition of sepsis**. The **updated definition** is a **dysregulated host immune response** to infection whereby the body's normal **localized immune response that progresses through a dysregulated systemic response to a life-threatening organ dysfunction.** Prior to 2016, sepsis was considered a clinical condition marked by the presence of both an infection and a systemic inflammatory response. It is now believed that **sepsis shock strongly relates to a loss of localized control of a body's excessive immune response due to endothelium damage, which allow a leak of proteins into the blood that ultimately leads to organ failure**.

The keys to successfully treating sepsis are early identification and prompt appropriate therapeutic treatment because **for every hour an appropriate antibiotic therapy is delayed, the risk of death increases by 7.6%**. Notably, sepsis presents a spectrum of symptoms/characteristics, which evolve over time as a patient **oscillates between a hyperinflammatory phase** and an **immune-suppressive phase**. By being able to identify an approaching inflammatory phase, **therapeutic treatments can be modified**, allowing for personalized care and an **improvement in patient outcomes**.

Volition is conducting and sponsoring research to determine that its **H3.1 biomarker test** has the potential to 1) **identify the waning and waxing of the inflammatory response** and 2) **determine therapeutic strategies for the sickest sepsis patients** and **those who are most likely to deteriorate**. Volition's research has shown that the H3.1 biomarker correlates well with the activation of neutrophil extracellular traps. So we have now got a clear scientific data showing that H3.1 directly links to niche for the activation.

Recent Events - Nu.Q NET Sepsis

In September 2023, Volition hosted a **key opinion leader roundtable event** (under the Volition's **Center of Excellence program**) in Athens, Greece. The sessions were very productive and thought-provoking, which led to many research initiatives. Another Center of Excellence roundtable event is planned for the Fall of 2024.

Just before the European Society of Intensive Care Medicine Conference (**ESICM**) on October 17, 2023, "Association of pronounced elevation of NET formation and nucleosome biomarkers with mortality in patients with septic shock" **was published** in Ann Intensive Care by Volition's clinical excellence group headed by Professor Gila Monterrey. The paper indicated that there is **a significantly positive correlation between the level of nucleosomes measured by Nu.Q NET level and sepsis**, particularly above 3.1 and organ failure, severity scores and mortality. In addition, the sickest patients with the highest nuclear levels were more like die. The paper at ESICM on October 24th.

Also on October 24, 2023, a paper entitled "Therapeutic Removal of cfDNA/NETs using NucleoCapture Apheresis in a Porcine Intensive Care Sepsis Model: A blinded randomized controlled trial" was presented at ESICM. In this study, NucleoCapture safely and effectively removed cfDNA/NETs from the circulation of septic pigs, which resulted in improved organ function and survival.

On December 13, 2023, a **paper entitled** "Novel rapid high-throughput method of NETosis Induction and Inhibition with physiological triggers and inhibitors**"** was posted on ***bioRxiv*****.**

On the March 26, 2024, management confirmed that Volition **completed the FDA Q-Submission process**, and the **FDA has confirmed that Volition can continue following a traditional 510-K pathway**.

Expected Nu.Q NET Sepsis Milestones in 2024/2025

- **Two large retrospective sepsis studies** are being conducted in Europe (a Sepsis Group Study in **Germany** and another at the **Amsterdam University Medical Center**). The outcome and trajectory of **over 2,500 patients with sepsis** will be examined (over 8,000 Nu.Q NET samples). The results are expected to be presented **at ESICM** (European Society of Intensive Care) in Barcelona **in October 2024**.

- In late 2024, Dr. Andrew Retter, recently appointed CMO, is expected to submit an article on Nu.Q NET's potential for the diagnosis and monitoring of sepsis for peer review and publication.

- Additional papers are expected from Volition's Centers of Excellence in 2024.

- A 500-patient study has been opened at **Guy's and Thomas's Hospital** that will compare 450 patients with sepsis to 50 healthy patients undergoing cardiac surgery. The study is expected to be completed in 2025, though interim analysis may be released during 2024.

INSTITUTIONAL OWNERSHIP

Over the last few months, institutional ownership has increased to over 9% of the outstanding shares.

VALUATION

Utilizing a financial model based on DCF methodology, which forecasts out to 2031, and uses a 10% discount rate (based on CAPM), a 2% terminal growth rate and a terminal P/S multiple of 0.49, the indicated value of VNRX is **$3.85 per share**.

Large Capitalization Industry Comparables	**Ticker**	**P/E Current FY**	**Mkt Cap ($billion)**	**TTM Price/ Book**	**TTM Price/ Sales**	**TTM EV/ EBITDA**
Industry Mean		**11.21**	**22.25**	**1.10**	**0.49**	**7.23**
Industry Median		11.99	15.32	1.32	0.36	7.72
ARCHER-DANIELS-MIDLAND CO	ADM	11.26	30.72	1.32	0.36	7.40
BASF SE	BASFY	12.36	43.07	1.10	0.62	8.08
BUNGE LIMITED	BG	12.85	15.32	1.45	0.28	5.11
WLMAR INTERNATIONAL LTD	WLMIY	7.60	14.50	0.72	0.22	7.83
INGREDION INC	INGR	11.99	7.64	2.03	0.98	7.72

RISKS

- VolitionRx is a clinical stage company. Since its formation, the company has incurred losses due to the continued spending on the time-consuming and costly efforts to discover and develop diagnostic products, including conducting clinical studies, obtaining regulatory clearance/approval in the United States, Asia and Europe Management expects continued losses from ongoing research and development expenses, along with administrative, manufacturing, sales and marketing expenses.

- Additional capital is required to continue funding management's strategic plan of commercializing the Nu.Q platform through the development of a suite of blood-based diagnostic tests. To date, VolitionRx has been successful in raising capital to fund the company's initiatives.

- As part of the effort to raise capital, shares outstanding have increased steadily over the last few years. Shares outstanding increased 15.6% in 2020, +16.3% in 2021, 5.1% in 2022 and 28.7% in 2023 as equity financings have helped fund the company's research & development costs and general corporate expenses. Commercialization of the company's products is expected to mitigate the rate of shareholder dilution.

- If third parties are believed to have infringed on the company's patents, the ensuing litigation would be time-consuming and costly. Conversely, third parties might believe that their proprietary rights have been infringed, which might also result in time-consuming and costly litigation, along with potentially impinging on Volition's ability to manufacture and sell certain future products

BALANCE SHEET

VolitionRx Limited					
(in $US except share data)	2020	2021	2022	2023	2024
Period ending	12/31/2020	12/31/2021	12/31/2022	12/31/2023	3/31/2024
ASSETS					
Cash and cash equivalents	19,444,737	20,581,313	10,867,050	20,729,983	11,772,163
Accounts receivable	7,118	12,510	72,609	242,617	133,500
Prepaid expenses	303,178	598,367	784,920	521,370	1,094,287
Other current assets	576,660	786,642	447,566	360,125	470,103
Total Current Assets	**20,331,693**	**21,978,832**	**12,172,145**	**21,854,095**	**13,470,053**
Property, plant and equipment	5,171,134	4,911,077	5,393,012	5,523,013	5,180,551
Operating lease right-of-use assets	326,085	383,551	619,392	549,504	569,163
Intangible assets	321,641	216,876	110,505	23,886	215,133
TOTAL ASSETS	**26,150,553**	**27,490,336**	**18,295,054**	**27,950,498**	**19,434,900**
Accounts payable	1,539,547	1,542,457	3,043,008	3,211,287	3,527,673
Accrued liabilities	3,491,740	3,841,013	2,872,247	3,928,761	3,305,316
Deferred revenue	-	-	10,000,000	23,000,000	23,000,000
Management and directors' fees payable	55,174	71,303	71,119	59,625	60,246
Current portion of long-term debt	841,319	797,855	1,066,700	1,207,007	1,149,944
Current portion of financing lease liabilities	59,930	48,958	46,014	126,649	47,875
Current portion of operating lease liabilities	179,624	171,166	245,163	48,570	201,047
Warrant liability	-	-	-	199,323	54,700
Current portion of grant repayable	69,218	43,100	41,836	55,855	145,571
Total Current Liabilities	**6,236,552**	**6,515,852**	**17,386,087**	**31,837,077**	**31,492,372**
Long-term debt	2,606,885	2,270,767	2,779,240	3,624,860	3,372,568
Financing lease liabilities	601,967	511,086	436,132	400,022	379,667
Operating lease liabilities	151,828	217,305	400,091	378,054	396,376
Grant repayable	259,603	253,221	420,466	422,707	413,968
Non-Current Liabilities	**3,620,283**	**3,252,379**	**4,035,929**	**4,825,643**	**4,562,579**
TOTAL LIABILITIES	**9,856,835**	**9,768,231**	**21,422,016**	**36,662,720**	**36,054,951**
SHAREHOLDERS' EQUITY					
Common Stock	48,607	53,772	57,873	81,898	82,109
Additional paid-in capital	126,526,239	154,730,938	164,397,468	194,448,414	194,997,353
Accumulated other comprehensive income	(59,978)	148,326	227,097	243,940	258,966
Accumulated deficit	(110,173,971)	(136,988,636)	(167,257,429)	(202,576,507)	(210,943,895)
Total VolitionRx Stockholders' Equity	**16,340,897**	**17,944,400**	**(2,574,991)**	**(7,802,255)**	**(15,605,467)**
Non-controlling interest	(47,179)	(222,295)	(551,971)	(909,967)	(1,014,584)
Total Stockholders' Equity	**16,293,718**	**17,722,105**	**(3,126,962)**	**(8,712,222)**	**(16,620,051)**
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	**26,150,553**	**27,490,336**	**18,295,054**	**27,950,498**	**19,434,900**
Shares outstanding	48,607,017	53,772,261	57,873,379	81,898,321	82,108,972

PROJECTED ANNUAL INCOME STATEMENTS

VolitionRx Limited


Income Statement (in $US, except share and per share data)	2020 12/31/2020	2021 12/31/2021	2022 12/31/2022	2023 12/31/2023	2024 E 12/31/2024
Product	11,321	90,035	210,993	598,457	1,306,759
Agreement Fee			0	0	0
Service (Contract lab services)	0	0	92,488	175,476	734,664
Royalty (Research kits)	2,112	0	2,911	1,369	0
Total Revenues	**13,433**	**90,035**	**306,392**	**775,302**	**2,041,423**
Expenses					
Research and development	14,533,862	15,541,889	14,572,532	19,551,523	15,389,443
General and administrative	5,654,018	8,751,392	10,937,686	10,368,314	8,422,493
Sales and marketing	1,073,368	4,129,833	6,576,246	6,843,160	5,503,798
Total Operating Expenses	**21,261,248**	**28,423,114**	**32,086,464**	**36,762,997**	**29,315,733**
Loss Before Other Income	**(21,247,815)**	**(28,333,079)**	**(31,780,072)**	**(35,987,695)**	**(27,274,310)**
Grant income	635,513	1,522,533	1,229,425	214,451	250,000
Interest income	49,495	2,734	125,265	93,324	34,616
Interest (expense)	(129,799)	(155,803)	(173,087)	(221,622)	(314,932)
Gain (loss) chg in FV of wt liab.	-	-	-	240,311	51,078
Gain on disposal of fixed assets	293,312	(26,166)	0	(15,843)	0
Other income (expense)	0	0	0	0	0
Total Other Income (Expenses)	**848,521**	**1,343,298**	**1,181,603**	**310,621**	**20,762**
Net Gain (Loss)	**(20,399,294)**	**(26,989,781)**	**(30,598,469)**	**(35,677,074)**	**(27,253,548)**
Net Gain (Loss) Non-Controlling Int.	(47,179)	(175,116)	(329,676)	(357,996)	(322,362)
Net Gain (Loss) - VNRX Stockholders	**(20,352,115)**	**(26,814,665)**	**(30,268,793)**	**(35,319,078)**	**(26,931,186)**
Basic and diluted loss per share	**(0.45)**	**(0.51)**	**(0.55)**	**(0.50)**	**(0.29)**
Wgted. Avg. Shares Out. - diluted	45,278,847	52,655,885	55,350,401	71,234,565	94,250,159

QUARTERLY INCOME STATEMENTS

VolitionRx Limited						
Income Statement (in $US except share and per share data)	**2022 12/31/2022**	**1Q 2023 3/31/2023**	**2Q 2023 6/30/2023**	**3Q 2023 9/30/2023**	**4Q 2023 12/31/2023**	**2023 12/31/2023**
Product	210,993	144,452	166,147	127,523	160,335	598,457
Agreement Fee	0	0	0	0	0	0
Service (Contract lab services)	92,488	5,356	50,163	37,688	82,269	175,476
Royalty (Research kits)	2,911	0	0	0	1,369	1,369
Total Revenues	**306,392**	**149,808**	**216,310**	**165,211**	**243,973**	**775,302**
Expenses						
Research and development	14,572,532	4,905,678	5,451,287	4,650,658	4,543,900	19,551,523
General and administrative	10,937,686	2,581,703	2,644,957	2,599,908	2,541,746	10,368,314
Sales and marketing	6,576,246	1,707,457	1,669,102	1,567,700	1,898,901	6,843,160
Total Operating Expenses	**32,086,464**	**9,194,838**	**9,765,346**	**8,818,266**	**8,984,547**	**36,762,997**
Loss Before Other Income	**(31,780,072)**	**(9,045,030)**	**(9,549,036)**	**(8,653,055)**	**(8,740,574)**	**(35,987,695)**
Grant income	1,229,425	165,795	0	48,656	0	214,451
Interest income	125,265	57,648	27,109	230	8,337	93,324
Interest (expense)	(173,087)	(51,322)	(58,321)	(53,980)	(57,999)	(221,622)
Gain (loss) chg in FV of wt liab.	0	0	28,971	220,874	(9,534)	240,311
Gain (loss) disposal of fixed assets	0	0	0	(15,913)	70	(15,843)
Other income (expense)	0	0	0	0	0	0
Total Other Income (Expenses)	**1,181,603**	**172,121**	**(2,241)**	**199,867**	**(59,126)**	**310,621**
Net Gain (Loss)	**(30,598,469)**	**(8,872,909)**	**(9,551,277)**	**(8,453,188)**	**(8,799,700)**	**(35,677,074)**
Net Gain (Loss) Non-Controlling Int.	(329,676)	(93,361)	(80,298)	(82,887)	(101,450)	(357,996)
Net Gain (Loss) - VNRX Stockholders	**(30,268,793)**	**(8,779,548)**	**(9,470,979)**	**(8,370,301)**	**(8,698,250)**	**(35,319,078)**
Basic and diluted loss per share	**(0.55)**	**(0.15)**	**(0.14)**	**(0.11)**	**(0.11)**	**(0.50)**
Wgted. Avg. Shares Out. - diluted	55,350,401	60,176,975	66,884,368	78,176,859	78,426,859	71,234,565

VolitionRx Limited						
Income Statement		**1Q**	**2Q E**	**3Q E**	**4Q E**	**Estimate**
	2023	**2024**	**2024**	**2024**	**2024**	**2024**
(in $US except share and per share data)	**12/31/2023**	**3/31/2024**	**6/30/2024**	**9/30/2024**	**12/31/2024**	**12/31/2024**
Product	598,457	131,759	200,000	350,000	625,000	1,306,759
Agreement Fee	0	0	0	0	0	0
Service (Contract lab services)	175,476	39,776	144,888	250,000	300,000	734,664
Royalty (Research kits)	1,369	0	0	0	0	0
Total Revenues	**775,302**	**171,535**	**344,888**	**600,000**	**925,000**	**2,041,423**
Expenses						
Research and development	19,551,523	4,629,527	4,250,000	3,586,639	2,923,277	15,389,443
General and administrative	10,368,314	2,253,743	2,112,500	2,056,250	2,000,000	8,422,493
Sales and marketing	6,843,160	1,672,769	1,450,000	1,277,010	1,104,019	5,503,798
Total Operating Expenses	**36,762,997**	**8,556,039**	**7,812,500**	**6,919,898**	**6,027,296**	**29,315,733**
Loss Before Other Income	**(35,987,695)**	**(8,384,504)**	**(7,467,612)**	**(6,319,898)**	**(5,102,296)**	**(27,274,310)**
Grant income	214,451	0	0	100,000	150,000	250,000
Interest income	93,324	8,654	8,654	8,654	8,654	34,616
Interest (expense)	(221,622)	(77,233)	(78,233)	(79,233)	(80,233)	(314,932)
Gain (loss) chg in FV of wt liab.	240,311	(18,922)	20,000	40,000	10,000	51,078
Gain (loss) disposal of fixed assets	(15,843)	0	0	0	0	0
Other income (expense)	0	0	0	0	0	0
Total Other Income (Expenses)	**310,621**	**(87,501)**	**(49,579)**	**69,421**	**88,421**	**20,762**
Net Gain (Loss)	**(35,677,074)**	**(8,472,005)**	**(7,517,191)**	**(6,250,477)**	**(5,013,875)**	**(27,253,548)**
Net Gain (Loss) Non-Controlling Int.	(357,996)	(104,617)	(87,151)	(72,465)	(58,129)	(322,362)
Net Gain (Loss) - VNRX Stockholders	**(35,319,078)**	**(8,367,388)**	**(7,430,040)**	**(6,178,012)**	**(4,955,746)**	**(26,931,186)**
Basic and diluted loss per share	**(0.50)**	**(0.10)**	**(0.09)**	**(0.07)**	**(0.05)**	**(0.29)**
Wgted. Avg. Shares Out. - diluted	71,234,565	81,956,660	85,030,035	88,103,410	91,176,784	94,250,159

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Steven Ralston, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover.

SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.